Celerion https://validator.w3.org/feed/docs/rss2.html Cellular Immunogenicity Automation PBMC Processing Services Neutralizing Antibody (NAb) Assays Anti-Drug Antibody (ADA) Assays Cell Therapy Testing Services Metabolite Profiling Services Gene Therapy Analytical Services Biosimilar Testing Services Biomarker Analysis Services Immunogenicity Testing Services Pharmacokinetics/Pharmacodynamics (PK/PD) Analysis Nucleic Acid Therapeutic Testing Services Small Molecule Testing Services Drug Conjugate Testing Services Monoclonal Antibody Testing Services Therapeutic Modalities Bioanalytical Science Services Leadership Team Events Signal to Noise versus Titer: Is it time to adopt a new paradigm for clinical immunogenicity assessment? ACCP 2026 Session Slides Celerion launches new Hybrid ECG Core Lab for Phase I clinics Celerion launches electronic laboratory notebook, achieving major milestone toward 100% paperless laboratories Celerion and BryanLGH Health System Form Alliance to Provide Dedicated Hospital Beds for Phase I Studies Celerion adds USP Clean Room, enabling efficient execution of microtracer and microdosing studies Celerion recognized as member of the UK Respiratory Therapeutic Capability Cluster Member of UK Respiratory Therapeutic Capability Cluster Celerion awarded prestigious LEED® Green Building Certification Celerion receives ANVISA certification Celerion announces highly automated ECG analysis enabling data delivery within 37 days from first patient dosed Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples Celerion appoints Dr. Raymond Farmen as Vice President of Global Bioanalytical Services Celerion receives license enabling Investigational Medicinal Products (IMPs) to be imported directly to their GMP-licensed facility Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality Celerion and Ricerca Biosciences announces “The Biosimilars Alliance” to offer clients a more effective development path for biosimilars Celerion announces expanded state-of-the-art ADME Suite in its Lincoln, Nebraska USA facility Celerion is the First CRO Headquartered in the USA to Receive Full Accreditation from AAHRPP Celerion Builds on Respiratory Capabilities With the Addition of an On-site Bronchoscopy Suite Celerion appoints Dr. Bruce Morimoto as Executive Director, Applied Translational Medicine Celerion Expands Belfast Facility with Containment Room to Enable Live Biologics and Vaccine Studies Celerion Appoints Clayton Dehn as Executive Director, Metabolic Diseases Celerion Appoints John Horkulak as Executive Director, Eurasian Site Operations Celerion Celebrates 80 Years of Conducting Business at Global Headquarters in Lincoln, Nebraska Celerion Opens Operations in South Korea at Seoul National University Hospital Clinical Trial Center Celerion and Korean Drug Development Fund Form Collaboration to Strengthen Early Phase Clinical Research in South Korea Celerion Selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium for The Beta Cell Project Celerion Appoints Dr. Robert Lester as Chief Cardiologist, Global Medical Director of Cardiac Safety Services Celerion Expands Ophthalmological Capabilities to Patient Populations in Collaboration with Queen’s University, Belfast Home